RFCA
GBT

R&F Capital Advisors’s Global Blood Therapeutics, Inc. GBT Stock Holding History

R&F Capital Advisors’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-10,219
Closed -$148K – 850
2016
Q4 		$148K Buy
+10,219
New +$180K 0.05% 435

Other funds holding GBT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
WSC
White Square Capital London, United Kingdom $14.7M AUM 151.72% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

R&F Capital Advisors's GBT Position: Q1 2017 in Review

R&F Capital Advisors sold out of Global Blood Therapeutics, Inc. (GBT) in Q1 2017, closing a stake of 10,219 shares — an estimated $148K sold.

R&F Capital Advisors first reported a position in GBT in Q4 2016 and held it in 1 quarter. The position peaked at $148K in Q4 2016. 116 funds tracked by Wall St. Rank hold GBT as of Q1 2017.

  • R&F Capital Advisors reported no remaining Global Blood Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
  • R&F Capital Advisors sold 10,219 Global Blood Therapeutics, Inc. shares in Q1 2017, an estimated $148K.
  • R&F Capital Advisors first reported a position in Global Blood Therapeutics, Inc. in Q4 2016 and held it in 1 quarter.
  • R&F Capital Advisors's Global Blood Therapeutics, Inc. position peaked at $148K in Q4 2016.
  • 116 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q1 2017.

Based on R&F Capital Advisors's 13F filing for Q1 2017, filed 15 May 2017.